RetiPharma, a Copenhagen, Denmark-based company developing products for the treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans, secured EUR 1.3m as funding in a convertible note which paid in tranches according to achievement of agreed milestones.
The Novo Nordisk Foundation’s BioInnovation Institute (BII) provided the funding.
The company will use the capital to prepare its lead drug RP001 for a clinical proof-of-concept study in patients with retinal detachment as well as to in source additional compounds.
Led by Henrik Vissing, CEO, RetiPharma is developing products for treatment of degenerative eye disorders based on an in vivo platform for translation from in vivo models to humans. The company has an exclusive licence from University of Copenhagen to IP on a family of neuroprotective peptides.
RP001 is a new peptide drug for intravitreal [eye] injection that already has demonstrated functional improvement of the sight as well as neuroprotection in several in vivo models.
It is being prepared for clinical study in patients with retinal detachment as a proof-of-concept indication.
The company is supported by a scientific and clinical team lead by David Woldbye, MD and Kristian Klemp, MD Chief Physician, specialized in retinal detachment surgery at Rigshospitalet.